Skoči na glavni sadržaj

Izlaganje sa skupa

IS OESTROGEN NEUROPROTECTIVE?

Mark Agius ; Academic Department of Psychiatry University of Cambridge, Bedfordshire and Luton Partnership Trust, UK
Helen Hockings ; Clare College Cambridge, UK
Charlotte Wilson ; Magdalene College Cambridge, UK
Dan Lane ; Bedford Hospital, UK


Puni tekst: engleski pdf 229 Kb

str. 120-127

preuzimanja: 871

citiraj


Sažetak

Neuro-protection in this context is an important concept in the treatment of patients in the early, prodromal phase of psychosis, otherwise known as the ‘At Ultra High Risk Mental State’. Neuro-protection as described here refers to the use of agents to control the process of apoptosis, which occurs more rapidly in the
earliest phases of schizophrenia. There is a need to identify medications with fewer side effects than anti-psychotics in order to treat at risk mental states, or prodromal psychosis. Studies have shown that schizophrenia occurs in males at an earlier age
than females. Later, at about the time of the menopause, there is a second peak in the incidence of psychosis (schizophrenia) in women. Hence it has been suggested that Oestrogen may be neuroprotective. Studies have shown that the addition of
oestradiol to anti-psychotics in the treatment of schizophrenia in females increased the efficacy of the treatment, which suggests that oestrogen does indeed have a neuroprotective action. However oestrogen has never been used in ‘at ultra high risk mental states’, perhaps because of concern regarding side effects.

Ključne riječi

schizophrenia; neuro-protection; prodrome; at risk mental state; oestrogen

Hrčak ID:

49528

URI

https://hrcak.srce.hr/49528

Datum izdavanja:

10.3.2009.

Posjeta: 1.255 *